BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26175307)

  • 1. Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 years.
    Jung KY; Kim SM; Yoo WS; Kim BW; Lee YS; Kim KW; Lee KE; Jeong JJ; Nam KH; Lee SH; Hah JH; Chung WY; Yi KH; Park DJ; Youn YK; Sung MW; Cho BY; Park CS; Park YJ; Chang HS
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):587-97. PubMed ID: 26175307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Preoperative Serum Calcitonin Levels for Predicting the Recurrence of Medullary Thyroid Carcinoma.
    Park H; Park SY; Park J; Choe JH; Chung MK; Woo SY; Choi JY; Kim SW; Chung JH; Kim TH
    Front Endocrinol (Lausanne); 2021; 12():749973. PubMed ID: 34675884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of lymph node ratio in Medullary thyroid carcinoma: A multi-center study.
    Rozenblat T; Hirsch D; Robenshtok E; Grozinsky-Glasberg S; Gross DJ; Mazeh H; Benbassat C; Twito O; Levy S; Mizrachi A; Shpitzer T; Bachar G
    Eur J Surg Oncol; 2020 Nov; 46(11):2023-2028. PubMed ID: 32389525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma.
    Guo F; Fu G; Li F; Hua Y; Wang Z; Zheng X; Zhao J; Gao M
    World J Surg Oncol; 2024 May; 22(1):121. PubMed ID: 38711029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasonographic Features of Medullary Thyroid Carcinoma: Do they Correlate with Pre and PostOperative Calcitonin Levels?
    Cho KE; Gweon HM; Park AY; Yoo MR; Kim J; Youk JH; Park YM; Son EJ
    Asian Pac J Cancer Prev; 2016; 17(7):3357-62. PubMed ID: 27509975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cure and survival of sporadic medullary thyroid carcinoma following systematic preoperative calcitonin screening.
    Torresan F; Mian C; Cavedon E; Iacobone M
    Langenbecks Arch Surg; 2019 Jun; 404(4):411-419. PubMed ID: 30903267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Follow-up in Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medullary thyroid cancer outcomes in patients with undetectable versus normalized postoperative calcitonin levels.
    Fanget F; Demarchi MS; Maillard L; Lintis A; Decaussin M; Lifante JC
    Br J Surg; 2021 Sep; 108(9):1064-1071. PubMed ID: 33899100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.
    Kim SJ; Yun HJ; Shin SJ; Lee YS; Chang HS
    Front Endocrinol (Lausanne); 2021; 12():747704. PubMed ID: 34803914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma.
    Kuo EJ; Sho S; Li N; Zanocco KA; Yeh MW; Livhits MJ
    JAMA Surg; 2018 Jan; 153(1):52-59. PubMed ID: 28973144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic variables and calcitonin in medullary thyroid cancer.
    Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
    Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer.
    Ho AS; Wang L; Palmer FL; Yu C; Toset A; Patel S; Kattan MW; Tuttle RM; Ganly I
    Ann Surg Oncol; 2015 Aug; 22(8):2700-6. PubMed ID: 25366585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy.
    Kwon H; Kim WG; Jeon MJ; Song DE; Lee YM; Sung TY; Chung KW; Yoon JH; Hong SJ; Baek JH; Lee JH; Kim TY; Kim WB; Shong YK
    Endocrine; 2016 Jul; 53(1):174-81. PubMed ID: 26754662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of patients with hypercalcitoninemia after initial treatment for medullary thyroid cancer and postoperative serum calcitonin cutoffs for predicting structural recurrence.
    Cho YY; Jang HW; Jang JY; Kim TH; Choe JH; Kim JH; Kim JS; Kim SW; Chung JH
    Head Neck; 2016 Oct; 38(10):1501-8. PubMed ID: 27062421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Undetectable Postoperative Calcitonin Level Is Associated with Long-Term Disease-Free Survival in Medullary Thyroid Carcinoma: Results of a Retrospective Cohort Study.
    Duval MADS; Ferreira CV; Marmitt L; Dora JM; Espíndola M; Benini AF; Camelier MV; Bulzico D; Andrade FA; Alves Júnior PA; Corbo R; Vaisman F; Zanella AB; Scheffel RS; Maia AL
    Thyroid; 2023 Jan; 33(1):82-90. PubMed ID: 36222615
    [No Abstract]   [Full Text] [Related]  

  • 16. Calcitonin doubling time in medullary thyroid carcinoma after the detection of distant metastases keenly predicts patients' carcinoma death.
    Ito Y; Miyauchi A; Kihara M; Kudo T; Miya A
    Endocr J; 2016 Jul; 63(7):663-7. PubMed ID: 27097545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medullary Thyroid Carcinoma: Prognostic Variables And Tumour Markers Affecting Survival.
    Hassan A; Siddique M; Riaz S; Khan AI; Nawaz MK; Bashir H
    J Ayub Med Coll Abbottabad; 2018; 30(Suppl 1)(4):S627-S632. PubMed ID: 30838820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer.
    Machens A; Lorenz K; Dralle H
    J Clin Endocrinol Metab; 2014 Aug; 99(8):2986-94. PubMed ID: 24840813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk factors of recurrence or metastasis in patients with medullary thyroid carcinoma].
    Guo FL; Li LJ; Ruan XH; Fu GM; Zhao JZ; Hou XK; Gao M; Zheng XQ
    Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(48):3849-3855. PubMed ID: 36540922
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine.
    Modigliani E; Cohen R; Campos JM; Conte-Devolx B; Maes B; Boneu A; Schlumberger M; Bigorgne JC; Dumontier P; Leclerc L; Corcuff B; Guilhem I
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):265-73. PubMed ID: 9578814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.